|  |
September 2010 Stock Report
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| HUMAN GENOME SCIENCES |
$28.63 |
83% |
57% |
$5,387 |
$611 |
$622 |
$5,398 |
$7.0 |
-$227 |
2.7 |
Dec-93 |
9.5 |
$3.00 |
$176 |
| INCYTE CORP. |
$15.11 |
99% |
129% |
$1,844 |
$441 |
$355 |
$1,757 |
$9.4 |
na |
na |
Nov-93 |
8.0 |
$1.88 |
$47 |
| MYRIAD GENETICS |
$16.40 |
59% |
-38% |
$1,543 |
$422 |
$0 |
$1,121 |
$1.6 |
na |
na |
Oct-95 |
1.8 |
$9.00 |
$163 |
| 1st
Generation Genomics Average |
|
81% |
49% |
$2,925 |
$491 |
|
$2,759 |
$6.0 |
na |
2.7 |
|
6.5 |
|
|
| 1st
Generation Genomics Median |
|
83% |
57% |
$1,844 |
$441 |
|
$1,757 |
$7.0 |
na |
2.7 |
|
8.0 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AFFYMETRIX |
$4.82 |
48% |
-45% |
$341 |
$305 |
$234 |
$270 |
$0.2 |
-$22 |
13.8 |
Jun-96 |
0.6 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$4.00 |
87% |
57% |
$201 |
$38 |
$12 |
$175 |
$0.3 |
na |
na |
Dec-99 |
0.3 |
$16.00 |
$333 |
| CEPHEID |
$18.86 |
90% |
42% |
$1,127 |
$48 |
$8 |
$1,086 |
$3.5 |
-$7 |
6.7 |
Jun-00 |
3.1 |
$6.00 |
$158 |
| COMBIMATRIX CORP. |
$2.26 |
29% |
-66% |
$17 |
$13 |
$0 |
$4 |
$0.1 |
na |
na |
na |
na |
na |
na |
| COMPUGEN LTD |
$4.74 |
81% |
66% |
$156 |
$21 |
$0 |
$135 |
$1.1 |
-$4 |
5.8 |
Sep-00 |
0.5 |
$10.00 |
na |
| ILLUMINA |
$50.17 |
99% |
23% |
$6,236 |
$805 |
$357 |
$5,788 |
$9.7 |
na |
na |
Jul-00 |
3.1 |
$16.00 |
$515 |
| ORCHID CELLMARK |
$1.52 |
69% |
-11% |
$46 |
$19 |
$0 |
$27 |
$0.1 |
-$6 |
2.9 |
May-00 |
0.2 |
$8.00 |
$263 |
| ROSETTA GENOMICS |
$1.22 |
35% |
-50% |
$20 |
$7 |
$0 |
$13 |
$0.3 |
-$18 |
0.4 |
Feb-07 |
0.2 |
$7.00 |
$79 |
| SEQUENOM |
$6.84 |
79% |
24% |
$513 |
$72 |
$4 |
$445 |
$4.2 |
-$237 |
0.3 |
Feb-00 |
0.3 |
$26.00 |
$609 |
| VERMILLION |
$5.38 |
16% |
-36% |
$56 |
$29 |
$13 |
$40 |
$0.3 |
-$3 |
10.4 |
Sep-00 |
0.0 |
$160.00 |
$417 |
| Genomic Supply Average |
|
63% |
0% |
$871 |
$136 |
|
$798 |
$2.0 |
-$42 |
5.8 |
|
0.9 |
|
|
| Genomic Supply Median |
|
74% |
6% |
$178 |
$33 |
|
$155 |
$0.3 |
-$7 |
5.8 |
|
0.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMICUS THERAPEUTICS |
$3.82 |
39% |
-60% |
$106 |
$69 |
$2 |
$38 |
$0.5 |
-$45 |
1.5 |
May-07 |
0.3 |
$15.00 |
$327 |
| ARENA PHARMACEUTICALS |
$1.61 |
20% |
-65% |
$181 |
$119 |
$139 |
$201 |
$0.5 |
-$115 |
1.0 |
Jul-00 |
0.1 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$6.89 |
89% |
9% |
$565 |
$323 |
$2 |
$244 |
$0.5 |
-$25 |
13.1 |
Feb-00 |
0.0 |
$225.00 |
na |
| EXELIXIS |
$4.17 |
52% |
-36% |
$453 |
$213 |
$356 |
$596 |
$0.9 |
-$90 |
2.4 |
Apr-00 |
0.3 |
$13.00 |
$520 |
| LEXICON PHARMACEUTICALS |
$1.48 |
52% |
-27% |
$499 |
$272 |
$28 |
$255 |
$0.4 |
-$101 |
2.7 |
Apr-00 |
0.1 |
$22.00 |
$1,037 |
| MAXYGEN |
$5.76 |
80% |
-13% |
$176 |
$155 |
$5 |
$26 |
$0.2 |
na |
na |
Dec-99 |
0.4 |
$16.00 |
$465 |
| ORE PHARMACEUTICALS |
$0.40 |
47% |
-42% |
$2 |
$0 |
$0 |
$2 |
$0.0 |
na |
na |
Nov-97 |
0.1 |
$8.00 |
$109 |
| RIGEL PHARMACEUTICALS |
$8.55 |
84% |
3% |
$446 |
$187 |
$48 |
$306 |
$2.0 |
na |
na |
Nov-00 |
1.2 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$3.63 |
42% |
-57% |
$164 |
$69 |
$1 |
$96 |
$1.3 |
-$15 |
4.5 |
Apr-00 |
0.2 |
$15.00 |
$312 |
| ZYMOGENETICS |
$9.73 |
99% |
58% |
$836 |
$205 |
$189 |
$819 |
$1.6 |
-$15 |
13.7 |
Feb-01 |
0.8 |
$12.00 |
$547 |
| Genomic Targets Average |
|
60% |
-23% |
$343 |
$161 |
|
$258 |
$0.8 |
-$58 |
5.6 |
|
0.3 |
|
|
| Genomic Targets Median |
|
52% |
-31% |
$313 |
$171 |
|
$222 |
$0.5 |
-$45 |
2.7 |
|
0.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXION PHARMACEUTICALS |
$63.54 |
99% |
41% |
$5,727 |
$266 |
$8 |
$5,470 |
$18.5 |
na |
na |
Feb-96 |
7.7 |
$8.25 |
$62 |
| CYPRESS BIOSCIENCE |
$3.82 |
46% |
-52% |
$147 |
$136 |
$5 |
$17 |
$1.1 |
-$7 |
18.9 |
Dec-83 |
0.0 |
$80.00 |
$33 |
| TRUBION PHARMACEUTICALS |
$4.57 |
85% |
-12% |
$93 |
$42 |
$15 |
$66 |
$0.8 |
-$23 |
1.9 |
Oct-06 |
0.4 |
$13.00 |
$208 |
| Autoimmune Average |
|
76% |
-8% |
$1,989 |
$148 |
|
$1,851 |
$6.8 |
-$15 |
10.4 |
|
2.7 |
|
|
| Autoimmune Median |
|
85% |
-12% |
$147 |
$136 |
|
$66 |
$1.1 |
-$15 |
10.4 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AFFYMAX |
$6.02 |
23% |
-74% |
$147 |
$143 |
$44 |
$47 |
$0.5 |
na |
na |
Dec-06 |
0.2 |
$25.00 |
$345 |
| ALLOS THERAPEUTICS |
$4.47 |
51% |
-43% |
$471 |
$122 |
$0 |
$349 |
$5.9 |
-$80 |
1.5 |
Mar-00 |
0.2 |
$18.00 |
$604 |
| ALSERES PHARMACEUTICALS |
$0.30 |
40% |
-44% |
$8 |
$0 |
$34 |
$42 |
$1.9 |
-$7 |
0.0 |
na |
na |
na |
na |
| ANTIGENICS |
$0.97 |
43% |
-54% |
$95 |
$29 |
$49 |
$115 |
$0.7 |
-$20 |
1.5 |
Feb-00 |
0.1 |
$18.00 |
$429 |
| ARIAD PHARMACEUTICALS |
$3.55 |
80% |
62% |
$393 |
$81 |
$11 |
$323 |
$3.1 |
na |
na |
May-94 |
0.4 |
$8.00 |
$124 |
| AVEO PHARMACEUTICALS |
$9.71 |
98% |
na |
$300 |
$107 |
$36 |
$229 |
$1.7 |
-$62 |
1.7 |
Mar-10 |
1.1 |
$9.00 |
$267 |
| AVI BIOPHARMA |
$1.94 |
87% |
20% |
$217 |
$38 |
$35 |
$214 |
$1.8 |
-$67 |
0.6 |
Jun-97 |
0.2 |
$9.00 |
$103 |
| CELL THERAPEUTICS |
$0.38 |
27% |
-69% |
$288 |
$65 |
$13 |
$236 |
$1.2 |
-$94 |
0.7 |
Mar-97 |
0.0 |
$10.00 |
$166 |
| CLEVELAND BIOLABS |
$5.08 |
88% |
41% |
$137 |
$6 |
$0 |
$131 |
$5.5 |
-$10 |
0.6 |
Jul-06 |
0.8 |
$6.00 |
$66 |
| CYTOKINETICS |
$2.67 |
48% |
-46% |
$172 |
$88 |
$0 |
$85 |
$0.6 |
-$53 |
1.7 |
Apr-04 |
0.2 |
$13.00 |
$839 |
| DENDREON CORP. |
$42.58 |
74% |
60% |
$6,131 |
$480 |
$77 |
$5,728 |
$24.7 |
-$570 |
0.8 |
Jun-00 |
4.3 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$2.50 |
91% |
123% |
$61 |
$18 |
$1 |
$44 |
$0.7 |
na |
na |
Jan-92 |
0.4 |
$6.00 |
$30 |
| ENTREMED |
$3.90 |
23% |
-30% |
$38 |
$8 |
$0 |
$30 |
$0.5 |
-$20 |
0.4 |
Jun-96 |
0.0 |
$165.00 |
$182 |
| GERON CORP. |
$5.36 |
75% |
-19% |
$546 |
$122 |
$1 |
$426 |
$4.1 |
-$68 |
1.8 |
Jul-96 |
0.7 |
$8.00 |
$77 |
| GTX |
$3.37 |
29% |
-74% |
$145 |
$28 |
$1 |
$118 |
$1.3 |
-$52 |
0.5 |
Feb-04 |
0.2 |
$14.50 |
$623 |
| IMMUNOGEN |
$5.69 |
52% |
-30% |
$387 |
$111 |
$4 |
$280 |
$1.5 |
-$54 |
2.1 |
Nov-89 |
0.6 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$3.22 |
55% |
-42% |
$242 |
$25 |
$0 |
$218 |
$2.1 |
na |
na |
Oct-83 |
2.6 |
$1.25 |
$25 |
| ONCOTHYREON |
$3.30 |
56% |
-38% |
$85 |
$0 |
$0 |
$85 |
$0.4 |
na |
na |
Jun-87 |
0.8 |
$4.40 |
$43 |
| ONYX THERAPEUTICS |
$27.03 |
81% |
-15% |
$1,695 |
$520 |
$292 |
$1,467 |
$11.7 |
-$389 |
1.3 |
May-96 |
2.3 |
$12.00 |
$105 |
| OPKO HEALTH |
$2.28 |
85% |
-6% |
$582 |
$20 |
$0 |
$562 |
$562.4 |
-$24 |
0.8 |
na |
na |
na |
na |
| OXIGENE |
$0.27 |
16% |
-82% |
$20 |
$7 |
$5 |
$18 |
$0.8 |
na |
na |
Oct-93 |
0.0 |
$6.00 |
$28 |
| PONIARD PHARMACEUTICALS |
$0.60 |
7% |
-92% |
$29 |
$29 |
$16 |
$16 |
$0.8 |
-$26 |
1.1 |
Aug-88 |
0.0 |
$168.00 |
$102 |
| PROGENICS PHARMACEUTICALS |
$5.05 |
72% |
-8% |
$166 |
$72 |
$1 |
$95 |
$0.5 |
-$61 |
1.2 |
Nov-97 |
0.6 |
$8.00 |
$70 |
| QLT |
$6.26 |
94% |
66% |
$328 |
$224 |
$0 |
$104 |
$0.4 |
-$4 |
54.9 |
Sep-86 |
5.8 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$2.59 |
58% |
-37% |
$124 |
$43 |
$0 |
$81 |
$0.5 |
na |
na |
Mar-92 |
0.3 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$12.16 |
85% |
-11% |
$1,231 |
$313 |
$24 |
$941 |
$6.2 |
-$33 |
9.4 |
Mar-01 |
1.7 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$4.10 |
58% |
-37% |
$206 |
$83 |
$15 |
$137 |
$2.7 |
-$39 |
2.1 |
na |
na |
na |
$198 |
| SUNESIS PHARMACEUTICALS |
$0.40 |
17% |
-14% |
$90 |
$49 |
$0 |
$40 |
$0.3 |
-$19 |
2.6 |
Sep-05 |
0.1 |
$7.00 |
$146 |
| SUPERGEN |
$2.11 |
56% |
-22% |
$127 |
$103 |
$1 |
$25 |
$0.3 |
na |
na |
Mar-96 |
0.4 |
$6.00 |
$21 |
| SYNTA PHARMACEUTICALS |
$3.91 |
56% |
29% |
$159 |
$49 |
$0 |
$110 |
$0.8 |
-$36 |
1.3 |
Feb-07 |
0.4 |
$10.00 |
$334 |
| THRESHOLD PHARMACEUTICALS |
$1.31 |
34% |
-26% |
$44 |
$26 |
$0 |
$18 |
$0.3 |
-$1 |
25.1 |
Feb-05 |
0.2 |
$7.00 |
$204 |
| Cancer Average |
|
57% |
-17% |
$473 |
$97 |
|
$397 |
$20.8 |
-$78 |
5.0 |
|
0.9 |
|
|
| Cancer Median |
|
56% |
-28% |
$166 |
$49 |
|
$115 |
$1.2 |
-$39 |
1.3 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ANTHERA PHARMACEUTICALS |
$4.20 |
49% |
na |
$94 |
$51 |
$0 |
$43 |
$3.0 |
-$32 |
1.6 |
Feb-10 |
0.6 |
$7.00 |
$193 |
| ARCA BIOPHARMA |
$3.76 |
41% |
3% |
$33 |
$11 |
$0 |
$23 |
$0.3 |
-$9 |
1.2 |
Sep-97 |
0.0 |
$280.00 |
$175 |
| CARDIOVASCULAR BIOTHERA. |
$0.27 |
65% |
37% |
$42 |
$0 |
$3 |
$45 |
$2.4 |
na |
na |
Feb-05 |
0.0 |
$10.00 |
$1,184 |
| MEDICINES COMPANY |
$14.97 |
97% |
32% |
$798 |
$219 |
$0 |
$580 |
$2.0 |
na |
na |
Sep-00 |
0.9 |
$16.00 |
$506 |
| QUESTCOR PHARMACEUTICALS |
$10.11 |
87% |
89% |
$628 |
$101 |
$18 |
$545 |
$10.9 |
na |
na |
na |
na |
na |
na |
| Cardiovascular Average |
|
68% |
40% |
$319 |
$76 |
|
$247 |
$3.7 |
-$20 |
1.4 |
|
0.4 |
|
|
| Cardiovascular Median |
|
65% |
35% |
$94 |
$51 |
|
$45 |
$2.4 |
-$20 |
1.4 |
|
0.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALBANY MOLECULAR RESEARCH |
$6.62 |
68% |
-23% |
$206 |
$66 |
$28 |
$168 |
$0.2 |
-$16 |
4.2 |
Feb-99 |
0.7 |
$10.00 |
$280 |
| ARQULE |
$5.35 |
71% |
11% |
$240 |
$109 |
$26 |
$157 |
$1.6 |
-$33 |
3.3 |
Oct-96 |
0.4 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$3.14 |
74% |
26% |
$168 |
$112 |
$168 |
$225 |
$0.8 |
-$63 |
1.8 |
Nov-01 |
0.4 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$4.75 |
37% |
-42% |
$213 |
$64 |
$3 |
$152 |
$2.9 |
-$10 |
6.2 |
Mar-94 |
0.7 |
$6.50 |
$47 |
| IRONWOOD PHARMACEUTICALS |
$10.30 |
69% |
na |
$1,007 |
$272 |
$38 |
$773 |
$4.7 |
-$69 |
4.0 |
Feb-10 |
0.9 |
$11.25 |
$1,096 |
| VERTEX PHARMACEUTICALS |
$36.88 |
83% |
1% |
$7,480 |
$979 |
$219 |
$6,721 |
$7.1 |
-$800 |
1.2 |
Jul-91 |
8.2 |
$4.50 |
$85 |
| Chemistry Average |
|
67% |
-5% |
$1,552 |
$267 |
|
$1,366 |
$2.9 |
-$165 |
3.4 |
|
1.9 |
|
|
| Chemistry Median |
|
70% |
1% |
$227 |
$110 |
|
$196 |
$2.3 |
-$48 |
3.6 |
|
0.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACADIA PHARMACEUTICALS |
$0.98 |
47% |
-44% |
$38 |
$34 |
$6 |
$10 |
$0.1 |
-$17 |
2.0 |
May-04 |
0.1 |
$7.00 |
$269 |
| ACORDA THERAPEUTICS |
$34.17 |
84% |
45% |
$1,329 |
$220 |
$51 |
$1,159 |
$17.3 |
-$27 |
8.1 |
Feb-06 |
5.7 |
$6.00 |
$118 |
| ADOLOR CORP |
$1.10 |
49% |
-33% |
$51 |
$62 |
$0 |
-$11 |
-$0.1 |
-$33 |
1.9 |
Nov-00 |
0.1 |
$15.00 |
$407 |
| CEPHALON |
$63.87 |
88% |
8% |
$4,803 |
$1,215 |
$1,014 |
$4,602 |
$1.6 |
na |
na |
Apr-91 |
3.5 |
$18.00 |
$155 |
| CORCEPT THERAPEUTICS |
$3.51 |
89% |
142% |
$253 |
$35 |
$0 |
$217 |
$21.7 |
-$23 |
1.6 |
Apr-04 |
0.3 |
$12.00 |
$864 |
| NEUROCRINE BIOSCIENCES |
$6.32 |
95% |
101% |
$347 |
$68 |
$12 |
$290 |
$1.1 |
-$35 |
2.0 |
May-96 |
0.6 |
$10.50 |
$172 |
| NUPATHE |
$7.61 |
74% |
na |
$110 |
$15 |
$5 |
$100 |
na |
-$23 |
0.7 |
Aug-10 |
0.8 |
$10.00 |
$142 |
| NYMOX PHARMACEUTICAL |
$3.36 |
62% |
-28% |
$108 |
$0 |
$0 |
$107 |
$1.1 |
-$7 |
0.1 |
na |
na |
na |
na |
| OMEROS CORPORATION |
$7.47 |
79% |
na |
$161 |
$42 |
$5 |
$124 |
na |
-$31 |
1.3 |
Oct-09 |
0.7 |
$10.00 |
$296 |
| OREXIGEN THERAPEUTICS |
$5.67 |
53% |
-41% |
$269 |
$63 |
$0 |
$206 |
$11.4 |
-$48 |
1.3 |
May-07 |
0.5 |
$12.00 |
$324 |
| PAIN THERAPEUTICS |
$6.36 |
91% |
29% |
$272 |
$181 |
$11 |
$101 |
$2.5 |
-$3 |
56.6 |
Jul-00 |
0.5 |
$12.00 |
$319 |
| PHARMOS CORP. |
$0.10 |
56% |
-38% |
$6 |
$4 |
$1 |
$3 |
$0.1 |
-$2 |
2.1 |
Jul-83 |
0.0 |
$20.00 |
$16 |
| TARGACEPT |
$23.15 |
93% |
18% |
$663 |
$241 |
$88 |
$509 |
$6.9 |
na |
na |
Apr-06 |
2.6 |
$9.00 |
$172 |
| TITAN PHARMACEUTICALS |
$0.87 |
35% |
-35% |
$52 |
$1 |
$2 |
$52 |
$1.4 |
-$7 |
0.2 |
Jan-96 |
0.2 |
$5.00 |
$66 |
| VANDA PHARMACEUTICALS |
$7.05 |
53% |
-40% |
$197 |
$207 |
$27 |
$18 |
$0.4 |
na |
na |
Apr-06 |
0.7 |
$10.00 |
$218 |
| CNS Average |
|
70% |
7% |
$577 |
$159 |
|
$499 |
$5.0 |
-$21 |
6.5 |
|
1.2 |
|
|
| CNS Median |
|
74% |
-28% |
$197 |
$62 |
|
$107 |
$1.4 |
-$23 |
1.7 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALEXZA PHARMACEUTICALS |
$3.49 |
89% |
47% |
$185 |
$42 |
$3 |
$146 |
$1.2 |
-$52 |
0.8 |
Mar-06 |
0.4 |
$8.00 |
$180 |
| ALKERMES |
$14.62 |
97% |
59% |
$1,396 |
$292 |
$0 |
$1,104 |
$1.5 |
-$54 |
5.4 |
Jul-91 |
2.9 |
$5.00 |
$70 |
| BIODELIVERY SCIENCES INT'L |
$2.86 |
54% |
-33% |
$69 |
$25 |
$0 |
$44 |
$3.4 |
na |
na |
na |
na |
na |
na |
| BIOMIMETIC THERAPEUTICS |
$11.63 |
74% |
-11% |
$323 |
$51 |
$0 |
$272 |
$8.5 |
-$31 |
1.7 |
May-06 |
1.5 |
$8.00 |
$122 |
| DEPOMED |
$4.21 |
66% |
1% |
$221 |
$67 |
$17 |
$171 |
$1.6 |
na |
na |
Nov-97 |
0.7 |
$6.10 |
$33 |
| DURECT CORP. |
$2.44 |
78% |
-12% |
$212 |
$54 |
$10 |
$168 |
$1.0 |
-$25 |
2.1 |
Sep-00 |
0.2 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$1.21 |
32% |
55% |
$54 |
$0 |
$31 |
$85 |
$0.8 |
-$55 |
0.0 |
Feb-89 |
0.2 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$11.12 |
96% |
39% |
$674 |
$440 |
$135 |
$368 |
$1.0 |
-$22 |
19.6 |
Feb-84 |
7.4 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$7.94 |
80% |
-10% |
$193 |
$35 |
$4 |
$162 |
$0.6 |
-$17 |
2.1 |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY |
$0.48 |
60% |
-33% |
$127 |
$20 |
$3 |
$110 |
$4.8 |
-$18 |
1.1 |
na |
na |
na |
na |
| INOVIO BIOMEDICALCORP |
$1.16 |
62% |
-21% |
$119 |
$25 |
$0 |
$95 |
$2.9 |
-$30 |
0.8 |
na |
na |
na |
na |
| MARINA BIOTECH |
$2.54 |
34% |
-53% |
$60 |
$2 |
$0 |
$58 |
$0.3 |
-$16 |
0.1 |
na |
na |
na |
na |
| MEDICIS PHARMACEUTICAL |
$30.06 |
99% |
43% |
$1,809 |
$631 |
$285 |
$1,462 |
$3.7 |
na |
na |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$14.86 |
94% |
49% |
$1,400 |
$345 |
$304 |
$1,359 |
$1.7 |
-$2 |
165.7 |
May-94 |
4.0 |
$3.75 |
$65 |
| NEUROGEX |
$6.63 |
63% |
-18% |
$118 |
$15 |
$8 |
$111 |
$3.0 |
-$41 |
0.4 |
May-07 |
0.6 |
$11.00 |
$143 |
| NOVAVAX |
$2.19 |
49% |
-42% |
$235 |
$27 |
$1 |
$209 |
$3.7 |
-$38 |
0.7 |
na |
na |
na |
na |
| XENOPORT |
$7.12 |
32% |
-67% |
$218 |
$105 |
$0 |
$113 |
$0.8 |
-$78 |
1.3 |
Jul-04 |
1.4 |
$5.00 |
$198 |
| Delivery Average |
|
68% |
0% |
$436 |
$128 |
|
$355 |
$2.4 |
-$34 |
14.4 |
|
1.9 |
|
|
| Delivery Median |
|
66% |
-11% |
$212 |
$42 |
|
$162 |
$1.6 |
-$31 |
1.2 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMAG PHARMACEUTICALS |
$18.24 |
35% |
-59% |
$384 |
$289 |
$12 |
$107 |
$2.6 |
-$85 |
3.4 |
na |
na |
na |
na |
| ENZO BIOCHEM |
$4.03 |
52% |
-45% |
$154 |
$34 |
$2 |
$122 |
$0.4 |
-$18 |
1.9 |
Jun-80 |
4.6 |
$0.87 |
$8 |
| EXACT SCIENCES CORP. |
$6.67 |
98% |
147% |
$269 |
$37 |
$7 |
$238 |
$4.9 |
-$10 |
3.8 |
Jan-01 |
0.5 |
$14.00 |
$261 |
| GENMARK DIAGNOSTICS |
$3.32 |
55% |
na |
$39 |
$30 |
$0 |
$9 |
$0.1 |
-$21 |
1.4 |
May-10 |
0.6 |
$6.00 |
$70 |
| GENOMIC HEALTH |
$13.77 |
63% |
-35% |
$397 |
$62 |
$2 |
$337 |
$1.8 |
na |
na |
Oct-05 |
1.1 |
$12.00 |
$286 |
| GEN-PROBE |
$47.85 |
93% |
18% |
$2,329 |
$506 |
$6 |
$1,829 |
$7.4 |
na |
na |
Sep-87 |
6.8 |
$7.00 |
$103 |
| HELICOS |
$0.58 |
19% |
-78% |
$46 |
$6 |
$11 |
$51 |
$0.6 |
-$19 |
0.3 |
May-07 |
0.1 |
$9.00 |
$188 |
| IDEXX LABORATORIES |
$60.56 |
88% |
21% |
$3,495 |
$161 |
$157 |
$3,491 |
$0.9 |
na |
na |
Jun-91 |
16.1 |
$3.75 |
$76 |
| IMMUCOR |
$19.72 |
87% |
14% |
$1,380 |
$217 |
$21 |
$1,184 |
$2.1 |
na |
na |
na |
na |
na |
na |
| LUMINEX CORP. |
$16.20 |
89% |
-5% |
$685 |
$105 |
$7 |
$587 |
$1.9 |
na |
na |
Mar-00 |
1.0 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$22.60 |
90% |
-4% |
$757 |
$58 |
$4 |
$702 |
$1.4 |
na |
na |
Nov-93 |
3.2 |
$7.00 |
$54 |
| MERIDIAN BIOSCIENCE |
$21.50 |
83% |
-15% |
$874 |
$58 |
$1 |
$817 |
$2.0 |
na |
na |
na |
na |
na |
na |
| MOLECULAR INSIGHT |
$0.78 |
12% |
-86% |
$20 |
$40 |
$0 |
-$20 |
-$0.5 |
-$69 |
0.6 |
Feb-07 |
0.1 |
$14.00 |
$343 |
| ONCOGENEX PHARMACEUTICALS |
$13.17 |
35% |
-63% |
$85 |
$47 |
$13 |
$51 |
$0.8 |
na |
na |
Oct-95 |
1.9 |
$7.00 |
$60 |
| ORASURE TECHNOLOGIES |
$4.08 |
60% |
36% |
$189 |
$75 |
$1 |
$115 |
$0.5 |
-$2 |
33.9 |
na |
na |
na |
na |
| QUIDEL CORP. |
$11.20 |
64% |
-32% |
$319 |
$28 |
$84 |
$375 |
$1.4 |
-$10 |
2.9 |
Aug-81 |
1.1 |
$10.00 |
$19 |
| RESPONSE GENETICS |
$2.38 |
73% |
40% |
$44 |
$7 |
$2 |
$39 |
$1.0 |
-$2 |
3.8 |
Jun-07 |
0.3 |
$7.00 |
$72 |
| TRINITY BIOTECH PLC |
$6.53 |
98% |
62% |
$138 |
$50 |
$0 |
$88 |
$0.1 |
na |
na |
na |
na |
na |
na |
| Diagnostic/imag. Average |
|
66% |
-5% |
$645 |
$101 |
|
$562 |
$1.6 |
-$26 |
5.8 |
|
2.9 |
|
|
| Diagnostic/imag. Median |
|
69% |
-5% |
$294 |
$54 |
|
$180 |
$1.2 |
-$18 |
2.9 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AASTROM BIOSCIENCES |
$1.56 |
38% |
-55% |
$44 |
$20 |
$0 |
$25 |
$0.4 |
-$20 |
1.0 |
Feb-97 |
0.2 |
$7.00 |
$88 |
| GENVEC |
$0.62 |
18% |
-20% |
$79 |
$43 |
$2 |
$38 |
$0.4 |
-$19 |
2.3 |
Dec-00 |
0.1 |
$9.50 |
$186 |
| OSIRIS THERAPEUTICS |
$7.74 |
84% |
5% |
$254 |
$84 |
$41 |
$211 |
$3.3 |
na |
na |
Aug-06 |
0.7 |
$11.00 |
$450 |
| STEMCELLS |
$0.77 |
45% |
-53% |
$98 |
$39 |
$1 |
$60 |
$1.3 |
-$21 |
1.9 |
Mar-92 |
0.1 |
$11.00 |
$82 |
| TENGION |
$3.02 |
58% |
na |
$37 |
$27 |
$15 |
$25 |
$0.4 |
-$50 |
0.5 |
Apr-10 |
0.6 |
$5.00 |
$62 |
| URIGEN PHARMACEUTICALS |
$0.06 |
30% |
-13% |
$5 |
$0 |
$5 |
$10 |
$1.2 |
-$8 |
0.0 |
Sep-97 |
0.0 |
$12.00 |
$161 |
| VICAL |
$2.27 |
51% |
-47% |
$128 |
$32 |
$1 |
$97 |
$0.7 |
-$34 |
0.9 |
Mar-93 |
0.5 |
$5.00 |
$52 |
| Gene/Cell therapy Average |
|
46% |
-31% |
$92 |
$35 |
|
$67 |
$1.1 |
-$25 |
1.1 |
|
0.3 |
|
|
| Gene/Cell therapy Median |
|
45% |
-34% |
$79 |
$32 |
|
$38 |
$0.7 |
-$21 |
0.9 |
|
0.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ACHILLION PHARMACEUTICALS |
$2.96 |
76% |
86% |
$114 |
$20 |
$0 |
$95 |
$1.5 |
-$26 |
0.8 |
Oct-06 |
0.3 |
$11.50 |
$178 |
| ADVANCED LIFE SCIENCES |
$0.05 |
15% |
-81% |
$10 |
$0 |
$8 |
$18 |
$1.0 |
-$8 |
0.0 |
Aug-05 |
0.0 |
$5.00 |
$85 |
| ANADYS PHARMACEUTICALS |
$2.22 |
69% |
-15% |
$96 |
$22 |
$3 |
$77 |
$0.8 |
-$12 |
1.9 |
Mar-04 |
0.3 |
$7.00 |
$302 |
| CELLDEX THERAPEUTICS |
$4.16 |
44% |
-16% |
$133 |
$66 |
$12 |
$79 |
$1.1 |
-$38 |
1.7 |
May-86 |
0.1 |
$48.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$23.55 |
97% |
15% |
$1,389 |
$478 |
$255 |
$1,166 |
$2.8 |
na |
na |
Oct-96 |
3.9 |
$6.00 |
$55 |
| DYNAVAX TECHNOLOGIES |
$1.79 |
76% |
1% |
$155 |
$57 |
$12 |
$109 |
$0.7 |
-$112 |
0.5 |
Feb-04 |
0.2 |
$7.50 |
$649 |
| EMERGENT BIOSOLUTIONS |
$18.29 |
92% |
-1% |
$572 |
$105 |
$49 |
$516 |
$1.1 |
na |
na |
Nov-06 |
1.5 |
$12.50 |
$342 |
| IDENIX PHARMACEUTICALS |
$2.99 |
49% |
-7% |
$218 |
$51 |
$12 |
$179 |
$0.8 |
-$65 |
0.8 |
Jul-04 |
0.2 |
$14.00 |
$684 |
| INHIBITEX |
$1.93 |
65% |
80% |
$120 |
$29 |
$1 |
$92 |
$1.1 |
-$22 |
1.3 |
Jun-04 |
0.3 |
$7.00 |
$435 |
| INTERMUNE |
$12.59 |
25% |
-20% |
$705 |
$87 |
$126 |
$744 |
$3.9 |
-$114 |
0.8 |
Mar-00 |
0.6 |
$20.00 |
$433 |
| MIDDLEBROOK PHARM. |
$0.08 |
4% |
-93% |
$7 |
$0 |
$0 |
$7 |
$0.1 |
na |
na |
Oct-03 |
0.0 |
$10.00 |
$224 |
| NABI BIOPHARMACEUTICALS |
$4.95 |
77% |
40% |
$213 |
$104 |
$15 |
$124 |
$0.2 |
-$14 |
7.6 |
na |
na |
na |
na |
| OPTIMER PHARMACEUTICALS |
$9.70 |
67% |
-30% |
$378 |
$67 |
$0 |
$311 |
$8.0 |
-$40 |
1.7 |
Feb-07 |
1.4 |
$7.00 |
$133 |
| PHARMASSET |
$29.08 |
86% |
39% |
$988 |
$144 |
$6 |
$850 |
$25.0 |
-$64 |
2.3 |
May-07 |
3.2 |
$9.00 |
$178 |
| SIGA TECHNOLOGIES |
$8.79 |
87% |
12% |
$402 |
$15 |
$5 |
$391 |
$8.9 |
-$18 |
0.8 |
Sep-97 |
1.8 |
$5.00 |
$32 |
| TRIUS THERAPEUTICS |
$4.20 |
77% |
na |
$99 |
$10 |
$20 |
$109 |
$2.9 |
-$9 |
1.1 |
Aug-10 |
0.8 |
$5.00 |
$118 |
| VIROPHARMA |
$15.13 |
100% |
69% |
$1,178 |
$421 |
$145 |
$902 |
$13.5 |
na |
na |
Nov-96 |
2.2 |
$7.00 |
$65 |
| XOMA LTD |
$3.00 |
23% |
-76% |
$64 |
$12 |
$20 |
$71 |
$0.3 |
-$62 |
0.2 |
Jun-86 |
0.0 |
$240.00 |
$140 |
| Infection Average |
|
63% |
0% |
$380 |
$94 |
|
$324 |
$4.1 |
-$43 |
1.5 |
|
1.0 |
|
|
| Infection Median |
|
72% |
-1% |
$184 |
$54 |
|
$117 |
$1.1 |
-$32 |
1.0 |
|
0.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMYLIN PHARMACEUTICALS |
$21.24 |
88% |
66% |
$3,052 |
$582 |
$757 |
$3,227 |
$2.1 |
-$177 |
3.3 |
Jan-92 |
1.5 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$22.40 |
90% |
25% |
$2,286 |
$348 |
$515 |
$2,453 |
$6.0 |
-$2 |
181.2 |
Aug-99 |
1.7 |
$13.00 |
$449 |
| INSMED |
$0.69 |
53% |
-13% |
$90 |
$125 |
$0 |
-$35 |
-$0.3 |
-$2 |
82.4 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$4.53 |
68% |
69% |
$267 |
$32 |
$0 |
$235 |
$5.9 |
-$21 |
1.5 |
Jul-00 |
0.5 |
$10.00 |
$194 |
| MANNKIND |
$6.06 |
54% |
-38% |
$799 |
$31 |
$360 |
$1,129 |
$2.1 |
-$169 |
0.2 |
Jul-04 |
0.4 |
$14.00 |
$446 |
| NPS PHARMACEUTICALS |
$6.68 |
86% |
55% |
$440 |
$150 |
$338 |
$628 |
$3.2 |
-$25 |
5.9 |
May-94 |
1.2 |
$5.50 |
$40 |
| REPROS THERAPEUTICS |
$0.53 |
21% |
-50% |
$19 |
$5 |
$0 |
$14 |
$1.7 |
-$5 |
1.0 |
Mar-93 |
0.1 |
$5.50 |
$19 |
| SAVIENT PHARMACEUTICALS |
$22.81 |
97% |
48% |
$1,542 |
$89 |
$24 |
$1,477 |
$22.0 |
-$20 |
4.4 |
Sep-83 |
1.8 |
$13.00 |
$68 |
| VIVUS |
$6.76 |
49% |
-33% |
$549 |
$175 |
$20 |
$394 |
$3.5 |
-$91 |
1.9 |
Apr-94 |
1.0 |
$7.00 |
$164 |
| Metabolic Average |
|
67% |
14% |
$1,005 |
$171 |
|
$1,058 |
$5.1 |
-$57 |
31.3 |
|
1.0 |
|
|
| Metabolic Median |
|
68% |
25% |
$549 |
$125 |
|
$628 |
$3.2 |
-$21 |
3.3 |
|
1.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| ALIMERA SCIENCES |
$9.16 |
81% |
na |
$114 |
$60 |
$0 |
$53 |
$2.5 |
-$16 |
3.7 |
Apr-10 |
0.8 |
$11.00 |
$338 |
| ALNYLAM PHARMACEUTICALS |
$13.27 |
56% |
-42% |
$559 |
$261 |
$84 |
$382 |
$3.1 |
-$59 |
4.5 |
May-04 |
2.2 |
$6.00 |
$253 |
| CODEXIS |
$9.39 |
63% |
na |
$321 |
$100 |
$5 |
$226 |
$0.8 |
-$16 |
6.3 |
Apr-10 |
0.7 |
$13.00 |
$390 |
| CORNERSTONE THERAPEUTICS |
$6.86 |
91% |
1% |
$176 |
$52 |
$16 |
$140 |
$0.8 |
-$2 |
32.3 |
May-04 |
1.0 |
$7.00 |
$303 |
| GENTIUM SPA |
$6.30 |
91% |
97% |
$94 |
$6 |
$6 |
$94 |
$1.4 |
na |
na |
Jun-05 |
0.7 |
$9.00 |
$71 |
| ICAGEN |
$1.24 |
13% |
-85% |
$7 |
$12 |
$2 |
-$3 |
$0.0 |
-$9 |
1.4 |
Feb-05 |
0.0 |
$64.00 |
$176 |
| METABOLIX |
$10.76 |
58% |
4% |
$289 |
$78 |
$0 |
$211 |
$4.3 |
-$38 |
2.1 |
Nov-06 |
0.8 |
$14.00 |
$267 |
| MOMENTA PHARMACEUTICALS |
$14.66 |
56% |
34% |
$664 |
$71 |
$4 |
$597 |
$3.9 |
-$60 |
1.2 |
Jun-04 |
2.3 |
$6.50 |
$294 |
| SUCAMPO PHARMACEUTICALS |
$3.45 |
57% |
-41% |
$144 |
$92 |
$7 |
$60 |
$1.2 |
-$1 |
76.6 |
Aug-07 |
0.3 |
$11.50 |
$479 |
| Other Average |
|
63% |
-5% |
$263 |
$81 |
|
$195 |
$2.0 |
-$25 |
16.0 |
|
1.0 |
|
|
| Other Median |
|
58% |
1% |
$176 |
$71 |
|
$140 |
$1.4 |
-$16 |
4.1 |
|
0.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AMGEN |
$56.32 |
91% |
-7% |
$53,981 |
$15,844 |
$11,732 |
$49,869 |
$2.5 |
na |
na |
Jun-83 |
160.9 |
$0.35 |
$175 |
| BIOGEN IDEC |
$56.42 |
94% |
13% |
$13,649 |
$1,188 |
$1,183 |
$13,644 |
$3.6 |
na |
na |
Sep-91 |
22.6 |
$2.50 |
$131 |
| CELGENE CORP. |
$58.46 |
89% |
7% |
$26,859 |
$3,517 |
$98 |
$23,441 |
$18.2 |
na |
na |
Jul-87 |
31.9 |
$1.83 |
$55 |
| GENZYME CORP. |
$71.60 |
100% |
26% |
$18,247 |
$1,212 |
$1,296 |
$18,331 |
$2.0 |
-$15 |
80.3 |
Jun-86 |
28.6 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$36.55 |
74% |
-21% |
$30,652 |
$2,533 |
$1,687 |
$29,806 |
$11.9 |
na |
na |
Jan-92 |
9.7 |
$3.75 |
$210 |
| Revenue-driven Average |
|
89% |
4% |
$28,678 |
$4,859 |
|
$27,018 |
$7.6 |
na |
na |
|
50.8 |
|
|
| Revenue-driven Median |
|
91% |
7% |
$26,859 |
$2,533 |
|
$23,441 |
$3.6 |
na |
na |
|
28.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| DYAX CORP. |
$2.42 |
52% |
-43% |
$238 |
$97 |
$65 |
$206 |
$1.3 |
-$21 |
4.6 |
Aug-00 |
0.2 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$8.65 |
57% |
-41% |
$858 |
$529 |
$222 |
$551 |
$2.0 |
-$101 |
5.3 |
May-91 |
0.9 |
$10.00 |
$116 |
| LIGAND PHARMACEUTICALS |
$1.60 |
65% |
-32% |
$187 |
$42 |
$24 |
$169 |
$1.4 |
-$1 |
37.5 |
Nov-92 |
0.2 |
$8.27 |
$131 |
| REGENERON PHARMACEUTICALS |
$26.74 |
87% |
32% |
$2,196 |
$306 |
$218 |
$2,108 |
$3.6 |
-$102 |
3.0 |
May-00 |
1.2 |
$22.00 |
$330 |
| SENOMYX |
$4.35 |
92% |
26% |
$168 |
$55 |
$15 |
$127 |
$1.1 |
-$19 |
2.9 |
Jun-04 |
0.7 |
$6.00 |
$232 |
| VERENIUM |
$3.27 |
46% |
-53% |
$40 |
$17 |
$109 |
$133 |
$0.5 |
-$18 |
0.9 |
Feb-00 |
0.1 |
$24.00 |
$840 |
| ZALICUS |
$1.27 |
63% |
-21% |
$113 |
$50 |
$0 |
$63 |
$1.2 |
na |
na |
Nov-05 |
0.2 |
$7.00 |
$171 |
| Screening Average |
|
66% |
-19% |
$543 |
$157 |
|
$480 |
$1.6 |
-$44 |
9.0 |
|
0.5 |
|
|
| Screening Median |
|
63% |
-32% |
$187 |
$55 |
|
$169 |
$1.3 |
-$20 |
3.8 |
|
0.2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
9/24/2010 close |
% of 52wk High |
% change since 9/25/2009 |
Market Cap ($M) |
Liquidity, Pro forma ($M) |
ST< Debt ($M) |
Company Valuation ($M) |
Valuation/
Employee ($M) |
Burn Rate, annualized ($M) |
Survival Index (Yrs) |
IPO Date |
Cash/
cash from IPO/
share |
Price/Share At IPO |
IPO Post-Money Valuation ($M) |
| AUXILIUM PHARMACEUTICALS |
$26.21 |
68% |
-24% |
$1,248 |
$165 |
$7 |
$1,090 |
$4.1 |
-$54 |
3.1 |
Jul-04 |
3.5 |
$7.50 |
$160 |
| BIODEL |
$5.33 |
85% |
11% |
$141 |
$24 |
$0 |
$117 |
$4.7 |
-$35 |
0.7 |
May-07 |
0.4 |
$15.00 |
$304 |
| CADENCE PHARMACEUTICALS |
$8.36 |
71% |
-25% |
$423 |
$69 |
$18 |
$373 |
$15.5 |
-$49 |
1.4 |
Oct-06 |
0.9 |
$9.00 |
$260 |
| CATALYST PHARMACEUTICAL |
$1.17 |
44% |
27% |
$23 |
$6 |
$0 |
$17 |
$4.3 |
-$5 |
1.1 |
Nov-06 |
0.2 |
$6.00 |
$72 |
| CUMBERLAND PHARMACEUTICALS |
$5.91 |
35% |
na |
$120 |
$75 |
$8 |
$53 |
$0.5 |
na |
na |
Oct-09 |
0.3 |
$17.00 |
$504 |
| EURAND N.V. |
$9.90 |
65% |
-32% |
$475 |
$38 |
$11 |
$448 |
$0.9 |
na |
na |
May-07 |
0.6 |
$16.00 |
$701 |
| JAZZ PHARMACEUTICALS |
$10.31 |
74% |
18% |
$401 |
$11 |
$49 |
$438 |
$2.2 |
-$26 |
0.4 |
May-07 |
0.6 |
$18.00 |
$441 |
| SANTARUS |
$2.62 |
45% |
-20% |
$153 |
$99 |
$24 |
$78 |
$0.2 |
na |
na |
Mar-04 |
0.3 |
$9.00 |
$527 |
| SOMAXON PHARMACEUTICALS |
$4.26 |
40% |
73% |
$150 |
$55 |
$0 |
$94 |
$2.6 |
-$23 |
2.4 |
Dec-05 |
0.4 |
$11.00 |
$198 |
| Specialty Average |
|
59% |
3% |
$348 |
$60 |
|
$301 |
$3.9 |
-$32 |
1.5 |
|
0.8 |
|
|
| Specialty Median |
|
65% |
-5% |
$153 |
$55 |
|
$117 |
$2.6 |
-$30 |
1.2 |
|
0.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
|
64% |
-4% |
$1,419 |
$255 |
|
$1,293 |
$5.8 |
-$48 |
8.1 |
|
2.8 |
|
|
| Grand Median |
|
66% |
-11% |
$218 |
$67 |
|
$170 |
$1.5 |
-$25 |
1.9 |
|
0.6 |
|
|
originally published 10/13/2010 |
